Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;100(11):709-717.
doi: 10.1016/j.cireng.2022.07.002. Epub 2022 Jul 16.

Characteristics and oncological results of epidermoid anal carcinoma: Comparison analysis between immunocompetent and immunosuppressed patients

Yolanda Saralegui Ansorena  1 , Jose Maria Enriquez-Navascues  2 , Carlos Placer Galan  2 , Nerea Borda Arrizabalaga  2 , Jose Luis Elosegui Aguirrezabala  2 , Garazi Elorza Echaniz  2 , Ane Etxart Lopetegi  2 , Ignacio Aguirre Allende  2
Affiliations

Characteristics and oncological results of epidermoid anal carcinoma: Comparison analysis between immunocompetent and immunosuppressed patients

Yolanda Saralegui Ansorena et al. Cir Esp (Engl Ed). 2022 Nov.

Abstract

Objective: Most evidence, including recent randomized controlled trials, analysing anal squamous cell carcinoma (SCC) do not consider immunocompromise patient population. The aim of this study was to compare clinical and oncological outcomes among immunocompetent and immunocompromised patients with anal squamous cell carcinoma.

Method: Multicentric retrospective comparative study including 2 cohorts of consecutive patients, immunocompetent and immunocompromised, diagnosed with anal SCC. This study evaluated clinical characteristics, clinical response to radical chemoradiotherapy (CRT) and long-term oncological results including both local and distant recurrence, overall survival (OS) and disease-free survival (DFS).

Results: A total of 84 patients, 47 (55.6%) female, diagnosed with anal SCC from January 2012 to December 2017 were included, 22 (26%) and 62 (74%) patients in immunocompromised and immunocompetent groups respectively. Patients in immunocompromised group were significantly younger (53 vs. 61 years; P = 0.001), with smaller tumoral size (P = 0.044) and reported higher rates of substance abuse including tobacco use (P = 0.034) and parenteral drug consumption (P = 0.001). No differences were found in administered therapies (P = 301) neither in clinical response to chemoradiotherapy (83 vs. 100%). Moreover, similar 5-year OS (60 vs. 64%; P = 0.756) and DFS (65 vs. 68%; P = 0.338) were observed.

Conclusion: The present study shows no significant differences in long-term oncological results among immunocompetent and immunocompromised patients diagnosed with anal SCC, with a similar oncologic treatment. This evidence might be explained due to the close monitoring and adequate therapeutic control of HIV positive patients.

Keywords: Anal squamous-cell carcinoma; Carcinoma escamoso anal; Disease-free survival; Immunocompetent; Immunocompromised; Inmunocompetente; Inmunodeprimido; Overall survival; Recidiva; Recurrence; Supervivencia global; Supervivencia libre de enfermedad.

PubMed Disclaimer